Morgan Stanley
SANA icon

Morgan Stanley’s Sana Biotechnology SANA Stock Holding History

Morgan Stanley’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98M Sell
1,139,782
-320,233
-22% -$1.03M ﹤0.01% 4388
2026
Q1 		$4.2M Buy
1,460,015
+174,970
+14% +$689K ﹤0.01% 4262
2025
Q4 		$5.23M Buy
1,285,045
+408,540
+47% +$1.83M ﹤0.01% 4136
2025
Q3 		$3.11M Sell
876,505
-603,290
-41% -$2.18M ﹤0.01% 4503
2025
Q2 		$4.04M Buy
1,479,795
+654,131
+79% +$1.35M ﹤0.01% 4230
2025
Q1 		$1.39M Sell
825,664
-1,084,555
-57% -$3.03M ﹤0.01% 4830
2024
Q4 		$3.11M Buy
1,910,219
+7,154
+0.4% +$21.3K ﹤0.01% 4370
2024
Q3 		$7.92M Buy
1,903,065
+284,724
+18% +$1.5M ﹤0.01% 3614
2024
Q2 		$8.84M Buy
1,618,341
+128,661
+9% +$1.03M ﹤0.01% 3412
2024
Q1 		$14.9M Buy
1,489,680
+756,278
+103% +$5.67M ﹤0.01% 2995
2023
Q4 		$2.99M Buy
733,402
+140,439
+24% +$517K ﹤0.01% 4268
2023
Q3 		$2.29M Buy
592,963
+3,140
+0.5% +$16.9K ﹤0.01% 4300
2023
Q2 		$3.52M Buy
589,823
+104,082
+21% +$600K ﹤0.01% 4026
2023
Q1 		$1.59M Buy
485,741
+37,587
+8% +$150K ﹤0.01% 4589
2022
Q4 		$1.77M Sell
448,154
-247,231
-36% -$1.21M ﹤0.01% 4536
2022
Q3 		$4.17M Sell
695,385
-231,638
-25% -$1.67M ﹤0.01% 3842
2022
Q2 		$5.96M Sell
927,023
-858,870
-48% -$5.47M ﹤0.01% 3601
2022
Q1 		$14.8M Buy
1,785,893
+1,055,116
+144% +$8.53M ﹤0.01% 2443
2021
Q4 		$11.3M Sell
730,777
-167,713
-19% -$3.23M ﹤0.01% 2821
2021
Q3 		$20.2M Buy
898,490
+39,182
+5% +$823K ﹤0.01% 2072
2021
Q2 		$16.9M Buy
859,308
+43,788
+5% +$992K ﹤0.01% 2339
2021
Q1 		$27.3M Buy
+815,520
New +$26.6M ﹤0.01% 1641

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Morgan Stanley's SANA Position: Q2 2026 in Review

Morgan Stanley reduced its Sana Biotechnology (SANA) stake by 22% in Q2 2026, selling an estimated $1.03M and leaving 1,139,782 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4388.

Morgan Stanley first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $27.3M in Q1 2021. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Morgan Stanley held 1,139,782 shares of Sana Biotechnology worth $3.98M as of Q2 2026.
  • Morgan Stanley sold 320,233 Sana Biotechnology shares in Q2 2026, an estimated $1.03M.
  • Sana Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4388 holding.
  • Morgan Stanley first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • Morgan Stanley's Sana Biotechnology position peaked at $27.3M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.